A 57-year-old patient presents for evaluation of right nipple discomfort. The patient has family history of a mother and sister with premenopausal breast cancer.
CLINICAL HISTORY
A 57-year-old patient presents for evaluation of right nipple discomfort. The patient has family history of a mother and sister with premenopausal breast cancer.
FINDINGS
Digital mammography shows area of calcifications (Figure 1a-b). Magnification views demonstrate intraductal pleomorphic microcalcifications in the right 11:00 area (Figure 1c).
No noted findings on physical exam or ultrasound.
(Figure 1a)
(Figure 1b)
(Figure 1c)
MRI imaging performed for extent of disease demonstrates linear beaded enhancement extending from nipple posteriorly for 8cm within the right breast upper outer quadrant (Figure 2a-b).
(Figure 2a)
(FIgure 2b)
DIAGNOSIS
Vacuum assisted stereotactic needle core biopsy of the right breast 11:00 microcalcifications reveals ductal carcinoma in situ.
DISCUSSION
This case demonstrates the benefit of multimodality imaging including digital mammography and breast magnetic resonance imaging (MRI) in this patient, which led to a diagnosis of ductal carcinoma in situ (DCIS). There has been some conflicting information in the literature regarding MRI and its usefulness in the evaluation of DCIS. For this patient, the MRI revealed the extensive area of involvement more so than mammography. This information was critical to the surgeon for surgical planning.
Stamatia Destounis, MD, is managing partner and a radiologist at Elizabeth Wende Breast Care in Rochester, NY.
What Emerging CT Research Reveals About Obesity and Post-Op Survival for Non-Small Cell Lung Cancer
January 29th 2025For those without low skeletal muscle mass on CT and myosteatosis, obese patients have a 23 percent lower risk of death than non-obese patients after undergoing curative resection for non-small cell lung cancer, according to newly published research.
Emerging PET Agent Garners Second FDA Fast Track Designation for Prostate Cancer Imaging
January 24th 2025In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.